Search

Displaying results 5821 - 5830 of 10000 in total
  1. Drug

    Zilebesiran

    go.drugbank.com/drugs/DB18929
    Investigational

    Zilebesiran is under investigation in clinical trial NCT06272487 (Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care

  2. Drug

    Isothipendyl

    go.drugbank.com/drugs/DB08802
    Investigational

    Isothipendyl is an antihistamine and anticholinergic used as an antipruritic.

  3. Drug

    Inositol 1,3-bisphosphate

    go.drugbank.com/drugs/DB02942
    Experimental

    The compound corresponds to the soluble headgroup of phosphatidylinositol 3-phosphate (PtdIns(3)P), an endosomal signaling lipid recognized by FYVE domains, and it has been used as a ligand in structural … Inositol 1,3-bisphosphate is a phosphorylated myo-inositol derivative and small molecule metabolite in which phosphate groups occupy the 1 and 3 positions of the inositol ring.

  4. Drug

    Kojic acid

    go.drugbank.com/drugs/DB01759
    Approved

    Mixtures: Skin White Pro Strength Kojic and Hyaluronic Skin Lightening Serum
  5. Drug

    Arylacenamide

    go.drugbank.com/drugs/DB05792
    Experimental

    SRBP-1, [sigma]-2, HSI and its relative SRBP-2. It is a dual agent with both immunomodulatory and antiproliferative activities.

  6. Drug

    AN0128

    go.drugbank.com/drugs/DB05054
    Investigational

    AN0128 is a good candidate for a topical antibiotic and is currently being developed by Anacor as a novel therapeutic for acne and atopic dermatitis. … Of particular importance is P. acnes and its causal role in acne vulgaris. The rise in antibiotic resistance of P. acnes to standard antibiotics necessitates the development of new treatment agents.

  7. Drug

    CY301

    go.drugbank.com/drugs/DB06382
    Experimental

    CY301 (Simplivir) is an investigational gene silencing compound developed by CytoGenix for the treatment of HSV.

  8. Drug

    Otelixizumab

    go.drugbank.com/drugs/DB05496
    Investigational

    Tolerx is developing otelixizumab to treat patients with type 1 diabetes, psoriasis and other autoimmune diseases such as rheumatoid arthritis. … Otelixizumab is believed to inhibit the function of autoreactive T cells, which are important in propagating autoimmune diseases, while inducing regulatory T cell pathways that promote immunological tolerance and

    Categories: Amino Acids, Peptides, and Proteins
  9. Drug

    CIGB 300

    go.drugbank.com/drugs/DB16464
    Investigational

    and adenocarcinoma of the cervix) … CIGB-300, is under investigation in clinical trials for its potential to treat various conditions, including NCT01639638 (recurrent and nonrecurrent condyloma) and NCT01639625 (squamous cell carcinoma

    Categories: Amino Acids, Peptides, and Proteins
  10. Drug

    Taspoglutide

    go.drugbank.com/drugs/DB14027
    Investigational

    Taspoglutide is a pharmaceutical drug, a glucagon-like peptide-1 agonist (GLP-1 agonist), under investigation for treatment of type 2 diabetes being codeveloped by Ipsen and Roche. … In September 2010 Roche halted Phase III clinical trials due to incidences of serious hypersensitivity reactions and gastrointestinal side effects. As of May 2013 no new trials had been registered.

    Categories: Amino Acids, Peptides, and Proteins, Hormones, Hormone Substitutes, and Hormone Antagonists